It functions as a dual GLP-1 and GIP receptor agonist , offering: Enhanced insulin secretion Delayed gastric emptying Appetite suppression Improved glycemic control Tirzepatide demonstrated impressive clinical outcomes in the SURMOUNT and SURPASS trials, with average weight loss of 15-22.5% and substantial A1C reductions
Tracking food intake can be helpful for patients with obesity, but is contraindicated in patients with an eating disorder
In animal models it has been associated with tendon, ligament, muscle and gut healing , angiogenesis and cytoprotection effects reported preclinically, not confirmed in controlled human trials
Advances in Neurobiology, 13, 197-232
Other ingredients Sunflower lecithin, hypromellose (capsule), magnesium stearate